Nasdaq:US$15.16 (+0.08) | HKEX:HK$23.05 (-0.45) | AIM:£2.25 (+0)
Search
Announcements
123456
7
891011121314151617
found Documents: 833
Announcements & Press Releases, Oncology / Immunology | 22 Jun 2021

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
– First selective MET inhibitor approval in China in this setting – – First regulatory approval for the oral, potent and selective MET tyrosine kinase inhibitor –   Hong Kong, Shanghai & Florham Park, NJ —Tuesday, June 22, 202
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Jun 2021

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors
– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51% in patients with advanced pancreatic NET –   Hong K
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 18 Jun 2021

Disclosure Update
Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 18, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today filed the Post Hearing Information Pack (the “PHIP”) with the Stock Exchange of Hong Kon
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 18 Jun 2021

HUTCHMED Launches Hong Kong Initial Public Offering
Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 18, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the launch of its Hong Kong public offering (the “Hong Kong Public Offering”),
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 20 May 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 8 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and provide a corporate update –   Hong Kong,
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 17 May 2021

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors
– HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones –   Hong Kong, Shanghai & Florham Park, NJ — Monday, May 17, 2021: HUTCHMED (China) Limited (“HUTCHME
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 7 May 2021

HUTCHMED to Attend Upcoming Investor Conferences
Hong Kong, Shanghai & Florham Park, NJ — Friday, May 7, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat a
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 4 May 2021

Change of Company Name
Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, May 4, 2021: HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, further to its “Results of Annual General Meeting” announcement
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 May 2021

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
– First NDA submission by HUTCHMED in the U.S.; product launch preparations underway –   Hong Kong, Shanghai & Florham Park, NJ — Monday, May 3, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces th
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Apr 2021

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China
— Single-arm study in ~180 patients, with ORR as primary endpoint — — Relapsed/refractory FL and MZL constitute approximately 25% of all NHL — — HMPL-689 trials are also underway in these and other NHL subtypes in the U.S., Europe an
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Apr 2021

Results of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 28, 2021: Hutchison China MediTech Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual G
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Apr 2021

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ: Friday, April 23, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on April 2
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 Apr 2021

Notification of Dilution of Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 14, 2021:  Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding[1] in HUTCHMED remains unc
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 8 Apr 2021

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Hong Kong, Shanghai & Florham Park, NJ — Thu
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Mar 2021

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
Hong Kong, Shanghai, & Florham Park, NJ: Monday, March 29, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) announces that on March 26, 2021, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Mar 2021

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies
— HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development —   Hong Kong, Shanghai & Florham Park, NJ — Monday, March 29, 2021: Hutchison China MediTech Limited (“HUT
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 26 Mar 2021

2020 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Friday, March 26, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that its 2020 Annual Report together with the Notice of Annual General Meeting and the Form of Pr
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 24 Mar 2021

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million
– Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets –   Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHME
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Mar 2021

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in combination with BeiGene’s tislelizumab in patients w
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 10 Mar 2021

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, March 10, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) announces that following the announcement of the 2020 annual results of HUTCHMED on March 4, 2021, 2,656 Ameri
Read More
View Announcement (PDF)
Group | 4 Mar 2021

Chi-Med becomes HUTCHMED
Today, we begin consolidating the two corporate identities that we have used since our inception.  Hutchison China MediTech, or Chi-Med, has been used as our group identity, while Hutchison MediPharma has been the identity of our novel drug R&D
Read More
Announcements & Press Releases, Group | 4 Mar 2021

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity
Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT  Hong Kong, Shanghai & Florham Park, NJ––Thursday, March 4, 2021:  Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM), a
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Feb 2021

Chi-Med to Announce 2020 Final Results
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, February 3, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Jan 2021

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, January 14, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presente
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 11 Jan 2021

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further dev
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2020

Blocklisting Six Monthly Return
London: Thursday, December 31, 2020: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2020

Total Voting Rights
London: Thursday, December 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2020, the issued share capital of Chi-Med consisted of 727,722,215 ordinary shares of US$0.10 e
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Coverage | 30 Dec 2020

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors
– Sulanda® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression o
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Dec 2020

Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
– Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acce
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group, Press Coverage | 22 Dec 2020

Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, December 22, 2020:  Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Heal
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 15 Dec 2020

Grant of Share Options under Share Option Scheme
London: Tuesday, December 15, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on December 14, 2020, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General
Read More
View Announcement (PDF)
Oncology / Immunology | 8 Dec 2020

Chi-Med Hosts Ground-breaking Ceremony for a Large-Scale Manufacturing Plant in Zhangjiang, Shanghai
Tuesday, December 8, 2020 Shanghai: Chi-Med (Nasdaq/AIM: HCM) today held a ground-breaking ceremony in Zhangjiang Hi-Tech Park, Shanghai, commencing construction of a large-scale manufacturing plant for innovative drugs. Representatives from the S
Read More
View Article (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Nov 2020

Total Voting Rights
London: Monday, November 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2020, the issued share capital of Chi-Med consisted of 727,702,215 ordinary shares of US$0.10 eac
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 27 Nov 2020

Notification of Dilution of Voting Rights
London: Friday, November 27, 2020:  Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding[1] in Chi-Med remains unchanged, at 332,478,770 ordinary shares
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 17 Nov 2020

Chi-Med Announces US$100 Million Equity Investment by CPP Investments
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Hong Kong, Shanghai, & Florham Park, NJ: Tuesday
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Nov 2020

Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, November 5, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be pre
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 30 Oct 2020

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences
Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Oct 2020

Total Voting Rights
London: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 30, 2020, the issued share capital of Chi-Med consisted of 711,025,545 ordinary shares of US$0.10 each,
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Sep 2020

Total Voting Rights
London: Wednesday, September 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2020, the issued share capital of Chi-Med consisted of 710,785,545 ordinary shares of US$0.1
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Sep 2020

Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology
  ― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ―   ― SANET-p results complement previously presented positive Pha
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Sep 2020

Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Sep 2020

Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
Hong Kong, Shanghai, & Florham Park, NJ: Friday, September 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metas
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 Sep 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth fa
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Aug 2020

Total Voting Rights
London: Friday, August 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 28, 2020, the issued share capital of Chi-Med consisted of 710,594,765 ordinary shares of US$0.10 each, w
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Aug 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020
Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 12 Aug 2020

Grant of Share Options under Share Option Scheme
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, August 12, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on August 11, 2020, it granted share options under the Share Option Scheme conditionally adopte
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Aug 2020

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP
Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it received scientific advice from the European Medicines Agency's (“EMA”) Committee for
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 30 Jul 2020

Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs
– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib –  – Two further NDAs submitted in China – savolitinib in
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jul 2020

Block Admission Application
London: Thursday, July 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces an application has been made to the London Stock Exchange plc for a block admission of 30,221,458 ordinary shares, par value of US$0.1
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Jul 2020

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreeme
Read More
Download Press Release (PDF)
123456
7
891011121314151617